ABOUT US

A wholly owned subsidiary of a global pharmaceutical supplier

OUR PRODUCTS

First to market pharmaceutical compounds; unique, therapeutically optimized combinations; value branded equivalents

CONTACT US

Need more information? Would like to provide feedback? Interested in collaboration?
Ajanta Alzor CCB2 Main W
Ajanta Tri-Senza2
Ajanta Kamagra Main W
Ajanta Kamagra Main W
Ajanta Maxivent2
Ajanta Glipten Main W
Ajanta Kamagra Main W
Ajanta Rosuprin2
Ajanta Dimezine222
Ajanta Kamagra Main W
Ajanta Kamagra Main W
Ajanta Fenostat2
Ajanta Kamagra Main W
Ajanta Co-Altria Ped2
Ajanta Alzor Plain Main W
Ajanta Alzor HCT Main W
Ajanta Alduet Main W
Ajanta Rosucol2
Ajanta Glyzeric Main W
Ajanta Tri-alzor Main W
Ajanta co-altria2
Ajanta Kamagra Main W
Ajanta Rosufen2
Ajanta Kamagra Main W
Ajanta Synactiv2
Ajanta Atenurix Main W
Ajanta Asenza Plus2
Ajanta Kamagra Main W
Ajanta Tamplus Main W
Ajanta Carveta Main W
Ajanta Nebiloc2
Ajanta Rosugrel2
Ajanta Razine Main W
Ajanta Kamagra Main W
Ajanta Warik2 Main W
Ajanta Neurogesic Main W
Ajanta Razine Tile WO
Ajanta Alduet Tile WO
Ajanta Dimezine22
Ajanta Fenostat
Ajanta Glyzeric Tile WO
Ajanta Kamagra Tile WO
Ajanta Nebiloc
Ajanta Neurogesic Tile WO
Ajanta Synactiv
Ajanta Neurogesic Logo
Ajanta Tamplus Logo
Ajanta Alzor HCT Logo
Ajanta Alzor Plain Logo
Ajanta Alduet Logo
Ajanta Fenostat Logo tile
Ajanta Glyzeric Logo
Ajanta Atenurix Logo
Ajanta Nebiloc logo tile
  • VIEW ALL
Ajanta Tri-alzor Main W
Tri-alzor
Helping More Patients Achieve Target BP
Ajanta Alduet Main W
Alduet
Start Living. A New Improved Way for Allergic Rhinitis
Ajanta Rosugrel2
Rosugrel
Dual Vascular Protection
Ajanta Neurogesic Main W
Nurogesic B
Dual Acting Relief for Diabetic Neuropathy
Ajanta Co-Altria Ped2
Co-Altria Ped
For Pediatric Patients with Allergic Rhinitis
Ajanta Glipten Main W
Glipten
Take Control of Type ll Diabetes
Ajanta Rosuprin2
Rosuprin
Dual Protection
Ajanta Alzor HCT Main W
Alzor HCT
Helping More Patients Achieve Target BP
Ajanta Atenurix Main W
Atenurix
Best in Class Anti-hyperuricemic Agent
Ajanta Dimezine222
Dimezine
Stops Vertigo Spinning Out of Control
Ajanta Nebiloc2
Nebiloc CCB
Ajanta Synactiv2
Synactiv
BIG on Effective.en
  • VIEW ALL
Ajanta Rosugrel2
Rosugrel
Dual Vascular Protection
Ajanta Razine Main W
Razine
Take control of Angina
Ajanta Synactiv2
Synactiv
BIG on Effective.en
Ajanta Kamagra Main W
Kamagra
Kamagra Inspires Confidence
Ajanta co-altria2
Co-Altria
A New Improved Way for Allergic Rhinitis
Ajanta Neurogesic Main W
Nurogesic B
Dual Acting Relief for Diabetic Neuropathy
Ajanta Tri-Senza2
Tri-Senza
Helps Bring HbA1c Back to Target
Ajanta Rosuprin2
Rosuprin
Dual Protection
Ajanta Atenurix Main W
Atenurix
Best in Class Anti-hyperuricemic Agent
Ajanta Alduet Main W
Alduet
Start Living. A New Improved Way for Allergic Rhinitis
Ajanta Warik2 Main W
Warik
Warik Saves
Ajanta Nebiloc2
Nebiloc CCB
  • VIEW ALL
  • LATEST ARTICLES
07.22.2014
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
Hyperuricemia is a frequent complication of chronic kidney disease (CKD). Febuxostat is a novel xanthine oxidase inhibitor that is metabolized...

Read more...

07.07.2014
Ajanta Pharma Philippines Inc introduces Glyzeric; the first fixed dose combination containing the gliclazide 80mg and metformin 500mg for the...

Read more...

06.18.2014
Tri-Senza, Fenostat and Dimezine, three new and first to market fixed dose combinations launched. Tri-Senza is a triple combination containing...

Read more...

05.08.2014
Fenostat, containing atorvastatin 10mg and fenofibrate 160mg, helps lower LDL cholesterol and triglycerides while increasing HDL cholesterol.

Read more...

05.05.2014
Dimezine (a fixed dose combination of dimenhydrinate 40mg and cinnarizine 20mg) is the first new treatment option for vertigo in...

Read more...

  • LATEST ARTICLES
07.22.2014
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
Hyperuricemia is a frequent complication of chronic kidney disease (CKD). Febuxostat is a novel xanthine oxidase inhibitor that is metabolized...

Read more...

07.07.2014
Ajanta Pharma Philippines Inc introduces Glyzeric; the first fixed dose combination containing the gliclazide 80mg and metformin 500mg for the...

Read more...

06.18.2014
Tri-Senza, Fenostat and Dimezine, three new and first to market fixed dose combinations launched. Tri-Senza is a triple combination containing...

Read more...

05.08.2014
Fenostat, containing atorvastatin 10mg and fenofibrate 160mg, helps lower LDL cholesterol and triglycerides while increasing HDL cholesterol.

Read more...

05.05.2014
Dimezine (a fixed dose combination of dimenhydrinate 40mg and cinnarizine 20mg) is the first new treatment option for vertigo in...

Read more...

ABOUT US

A wholly owned subsidiary of a global pharmaceutical supplier

OUR PRODUCTS

First to market pharmaceutical compounds, unique therapeutically optimized combinations, value branded equivalents

CAREERS @ AJANTA

Looking for a challenging and rewarding career?

Apply here

PATIENT RESOURCES

Links to online educational materials